Moreover, the recruited B cells can express IgA, IL10, and PD‐L1, which are activated through the TGF‐β receptor pathway.[69] These B cells may suppress the anti‐tumor function of CD8+ T cells in the PCa tumor microenvironment, thereby contributing to oxaliplatin resistance. Here, CD79A is linked to neoplasm.